DavidHummel

i would put my entire networth (-$305k) on anthropic equity right now

The biggest cliche in higher ed is that STEM classes are hard and humanities/social sci classes are fluff. But how often I see STEM majors fighting for their lives if there are more than 40 pages of reading per class or essay assignments that presume they've done the reading.

The biggest cliche in higher ed is that STEM classes are hard and humanities/social sci classes are fluff. But how often I see STEM majors fighting for their lives if there are more than 40 pages of reading per class or essay assignments that presume they've done the reading.

Every single real Kanye fan has the same favorite Kanye song, you can actually tell 100% of the time if someone is a real fan by asking them this.

Here’s the truth: we’ve already reached AGI — we just haven’t implemented it broadly. Millions of jobs are being lost as we speak. Entire careers will be retired. The rich and powerful investors and founders who implement AGI will get bizarrely rich beyond what makes sense. It will break people's brains on both sides. It’s gonna suck for a lot of our friends and family, who aren’t obsessed with their careers, because things are moving so fast they won’t have even left the starting gate by the time the awards are handed out. We’re gonna have to solve for a lot of second- and third-order effects, some of which will suck (job loss) and some of which will be awesome. AI will create free/cheap energy, free education, cheaper and better food, homes that build themselves and medicine that makes you as healthy as a 30-year-old when you’re 100. … change is hard, but humans are the most adaptable species nature has ever created. We can figure it out.

now that i'm doing actual research instead of just engineering i realize lecun was right and elon was wrong

😆

Ozempic activates a 'repair mode' in cartilage cells, boosting joint thickness by 17% and potentially reducing the need for invasive surgeries. For years, experts assumed that the joint pain relief seen with Ozempic was mainly due to weight loss. A landmark 2026 study has challenged that view. Researchers from the Shenzhen Institutes of Advanced Technology discovered that semaglutide—the active ingredient in Ozempic—acts directly on cartilage cells (chondrocytes) to promote regeneration. By reprogramming the cells' energy metabolism (shifting from inefficient glycolysis toward more efficient oxidative phosphorylation via the GLP-1R-AMPK-PFKFB3 pathway), the drug helps trigger a restorative process that rebuilds the protective cartilage cushioning in joints—tissue long thought to be irreplaceable once lost. The results are striking. In a small pilot clinical study, advanced MRI scans showed an average 17% increase in cartilage thickness after six months of treatment, along with signs of new cartilage growth in weight-bearing areas. Patients also experienced reduced pain and improved joint function. This breakthrough points to a new way of treating osteoarthritis: not just managing symptoms, but addressing the underlying structural damage. While larger trials are still needed, semaglutide is emerging as a promising option that could help millions of people avoid or delay joint replacement surgeries and restore mobility through direct cellular repair—independent of its well-known weight-loss effects. [Qin, H., Yu, J., Yu, H., et al. (2026). Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism. Cell Metabolism, 38(3), 582–597.e6. DOI: 10.1016/j.cmet.2026.01.008]